Sellas Life Sciences reported that its experimental immunotherapy galinpepimut-S reduced the risk of death by 41% compared to standard therapy. The Phase 3 trial focused on individuals diagnosed with an advanced form of acute myeloid leukemia. By meeting its primary survival goal, the trial effectively refuted an earlier September column that anticipated the drug would fail.
Key points
Galinpepimut-S achieved its main therapeutic objective by significantly improving patient…: Galinpepimut-S achieved its main therapeutic objective by significantly improving patient survival rates against standard care.
The positive clinical findings directly countered skeptical predictions published in a Se…: The positive clinical findings directly countered skeptical predictions published in a September column regarding the drug's efficacy.
Sellas Life Sciences has secured critical Phase 3 validation for its advanced blood cance…: Sellas Life Sciences has secured critical Phase 3 validation for its advanced blood cancer treatment candidate.
Sources checked by our analysis pipeline: 1
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.
In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Physician-scientist John Powers III has taken permanent leadership of the National Institute of Allergy and Infectious Diseases following the contentious departure of Jeanne Marrazzo in 2025. Having previously served as acting director since June, he favors redirecting research resources away from HIV and pandemic readiness toward wider immunology initiatives alongside the broader agency leadership.
British health authorities have chosen to waive an approaching break clause that would have permitted an early departure from the massive data analytics agreement. This decision ensures that the technology firm remains an integral data partner for the healthcare system across the latter half of the decade. The shift establishes an expected five-year operational horizon rather than an immediate exit.
Palestinian officials and the Israeli military have offered starkly conflicting accounts following a fatal confrontation linked to a newly established settler outpost in al-Duyuk al-Tahta. While local reports state Israeli settlers initiated gunfire outside a family residence, the Israel Defense Forces maintained that Israelis discharged weapons in self-defense following a deliberate vehicle ramming and physical assault. The deadly event coincides with mounting international scrutiny and fresh British economic pen…